Answers are grounded in this paper and cite their sources.
e12627 Background: Response to neoadjuvant chemotherapy (NACT) in hormone receptor-positive, HER2-negative (ER+/HER2-) breast cancer (BC) is heterogeneous. Genomic assays predict chemotherapy benefit but are not widely available. We evaluated a clinicopathologic model estimating the probability of high genomic risk as a predictor of response to dose-dense NACT (AC q2w followed by Docetaxel q3w). Methods: We retrospectively analyzed 280 patients with stage II-III ER+/HER2- BC treated with NACT (median age 45 years; 70,3% premenopausal) in a single center. Most patients had locally advanced disease (86,8%), nodal involvement (93,9%), and luminal B subtype (95,4%). Pathologic response was assessed using Residual Cancer Burden (RCB). The probability of high genomic risk (corresponding to Recurrence Score ≥26) was calculated using the model developed by S. Yamamoto et al. according to the following formula: p = 1 / {1 + exp [−(4.611 + 1.2342×HER2 − 0.0813×ER − 0.0489×PR + 0.0857×Ki-67)]}, where HER2=0-2; ER, PR, Ki-67=% positive nuclei. A cutoff of ≥50% was predefined as in the original study since the accuracy, sensitivity, specificity, positive predictive and negative predictive values are 90,5%, 72,2%, 94,8%, 76,4% and 93,5%, respectively. Univariable and multivariable logistic regression analyses were performed to identify predictors of favorable response (RCB 0-1). RCB 0-1 as an end point was chosen due comparable long-term results in ER+/HER2- BC as per meta-analysis. Results: RCB 0 was achieved in 12,9% of patients and RCB 0-1 in 24,3%. Mean probability of high genomic risk was 40,3%, with 36,8% classified as high probability (≥50%). Germline testing was performed in 83,2% of patients; mutations (BRCA1/2, ATM, PALB2, CHEK2) were identified by NGS in 18,0% of all tested cases (BRCA2 being the most common - 9%) and were slightly more frequent in patients with high vs low genomic risk probability (22,2% vs 15,2%). In univariable analysis, factors associated with RCB 0-1 included age ≤50 years (OR 2,09, 95% CI 1,07-4,07), initially operable disease (OR 2,44, 95% CI 1,19-5,04), T1–3 stage (OR 1,80, 95% CI 1,03-3,13), presence of germline mutations (OR 2,82, 95% CI 1,41-5,67), and high genomic risk probability ≥50% (OR 2,64, 95% CI 1,51-4,62; all p <0,05). In multivariable analysis, high genomic risk probability ≥50% remained an independent predictor of RCB 0-1 (OR 2,80, 95% CI 1,48-5,30; p =0,001), together with germline mutation status (OR 2,32, 95% CI 1,11-4,85; p =0,025), while age, T stage and operability were not significant. Survival analysis is ongoing. Conclusions: A clinicopathologic model estimating the probability of high genomic risk independently predicts response to NACT in luminal breast cancer and may support selection of ER+/HER2- patients most likely to benefit from NACT when genomic testing is unavailable.
No takes yet. Share an insight, caveat, or question.
Kovalenko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: